Human antibody titres to coronavirus infection are found to be short lived

A study shows that people infected with coronaviruses have short-lived active antibodies, but have a mild infection a year later if re-exposed. [1]

This is problematic for a vaccine which would expect a long-lived immune response.  Early treatment approaches against viral infections have been demonstrated to be cheap and effective.